Acadian Asset Management
BCLI

Acadian Asset Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Acadian Asset Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,393
Closed -$118K – 1676
2021
Q3 		$118K Sell
2,393
-6,896
-74% -$363K ﹤0.01% 1413
2021
Q2 		$529K Buy
+9,289
New +$496K ﹤0.01% 1135
2018
Q4 		– Sell
-818
Closed -$47K – 1720
2018
Q3 		$47K Buy
+818
New +$49.4K ﹤0.01% 1374

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management's BCLI Position: Q4 2021 in Review

Acadian Asset Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 2,393 shares — an estimated $118K sold.

Acadian Asset Management first reported a position in BCLI in Q3 2018 and held it in 3 quarters. The position peaked at $529K in Q2 2021. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • Acadian Asset Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • Acadian Asset Management sold 2,393 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $118K.
  • Acadian Asset Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2018 and held it in 3 quarters.
  • Acadian Asset Management's BRAINSTORM CELL THERAPUTC position peaked at $529K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on Acadian Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.